用于治疗青光眼的大麻素。
Cannabinoids for treatment of glaucoma.
作者信息
Novack Gary D
机构信息
aDepartments of Pharmacology and Ophthalmology, University of California, Davis bPharmaLogic Development, Inc., San Rafael, California, USA.
出版信息
Curr Opin Ophthalmol. 2016 Mar;27(2):146-50. doi: 10.1097/ICU.0000000000000242.
PURPOSE OF REVIEW
The purpose of this article is to review the current status of cannabis in the treatment of glaucoma, including the greater availability of marijuana in the USA.
RECENT FINDINGS
The potency of marijuana, as measured by the concentration of Δ-tetrahydrocannabinol, has increased from ∼2 to 3% in the 1970s to ∼20% today. Many US states have passed laws allowing either medicinal or recreational use of marijuana.
SUMMARY
The pharmacology of marijuana and its effect on intraocular pressure has not changed since the research in the 1970s and 1980s. Marijuana is an effective ocular hypotensive agent. However, cardiovascular and neurological effects are observed at the same dose, and may theoretically reduce the beneficial effect of lowering intraocular pressure by reducing ocular blood flow. The clinician must be cognizant of this potential in diagnosis, prognosis, and therapy.
综述目的
本文旨在综述大麻在青光眼治疗中的现状，包括美国大麻获取的便利性增加的情况。
最新发现
以Δ-四氢大麻酚浓度衡量，大麻的效力已从20世纪70年代的约2%至3%增至如今的约20%。美国许多州已通过法律允许医用或娱乐用大麻。
总结
自20世纪70年代和80年代的研究以来，大麻的药理学及其对眼压的影响并未改变。大麻是一种有效的降眼压药物。然而，在相同剂量下会观察到心血管和神经方面的影响，理论上可能会因减少眼血流量而降低降低眼压的有益效果。临床医生在诊断、预后和治疗中必须认识到这种可能性。
Zotero 插件